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The rapid detection of Mycobacterium tuberculosis isolates resistant to second-line drugs is crucial for the
institution of appropriate treatment regimens as early as possible. Although molecular methods have success-
fully been used for the rapid detection of resistance to ﬁrst-line drugs, there are limited data on mutations that
confer resistance to second-line drugs. To address this question, we analyzed Mycobacterium tuberculosis strains
resistant to oﬂoxacin (n  26) and to capreomycin and/or amikacin (n  48) from Uzbekistan for variations
in target genes (gyrA, gyrB, rrs, and tlyA). Strains susceptible to oﬂoxacin (n  49) and capreomycin and/or
amikacin (n  39) were included as controls. Mutations in gyrA or gyrB were found in 96% (25/26 strains) of
the oﬂoxacin-resistant strains, while none of the susceptible strains displayed mutations in those two genes.
The most common mutation occurred in gyrA at codon 94 (17/26 strains [65.4%]), followed by mutations at
codons 90 and 91. Two strains showed a mutation in gyrB, at codons 485 and 543, respectively; both mutations
have not been reported previously. The most frequent mutation in strains resistant to both amikacin and
capreomycin was A1401G in rrs (34/40 strains [85.0%]). Three strains had mutations in tlyA, of which two (at
codons 18 and 118) were associated with resistance to capreomycin alone. Overall, none of the 10 resistant
strains (5 amikacin-resistant and capreomycin-susceptible strains) and none of the 39 susceptible control
strains had mutations in the genes investigated. Our results clearly demonstrate the potential of sequence
analyses of short regions of relatively few target genes for the rapid detection of resistance to second-line drugs
among strains isolated from patients undergoing treatment for multidrug-resistant tuberculosis. The mecha-
nisms that confer amikacin resistance in this setting remain unclear.
With 9.2 million new cases and 1.7 million deaths in 2006,
tuberculosis (TB) remains one of the most serious infectious
diseases worldwide (28). In many settings, the emergence and
transmission of drug-resistant Mycobacterium tuberculosis
strains further threaten TB control efforts. TB fails to respond
to treatment with the standard ﬁrst-line drugs isoniazid (INH)
and rifampin (RIF; rifampicin) in patients infected with so-
called multidrug-resistant (MDR) Mycobacterium tuberculosis
strains. MDR-TB is particularly difﬁcult to treat because the
second-line drugs used are less potent and more expensive
(12).
Disease caused by extensively drug-resistant (XDR) M. tu-
berculosis isolates, deﬁned as MDR with resistance to any
ﬂuoroquinolone and at least one of three injectable second-
line drugs (amikacin [AMK], capreomycin [CM], or kanamy-
cin), is associated with very poor treatment outcomes (9).
The rapid detection of microbial resistance to second-line
drugs prior to and during treatment is therefore of essential
importance for the implementation of increased infection con-
trol measures that may well limit the spread of TB to other
patients.
Compared to conventional liquid medium-based drug sus-
ceptibility testing, which still takes about 7 to 10 days, begin-
ning from the time that a positive culture is obtained (18), the
detection of genetic variants which mediate resistance to cer-
tain antimicrobial agents represents a more rapid alternative.
Tests for the detection of MDR M. tuberculosis that detect
mutations in the rpoB and katG/inhA regions, which confer
resistance to RIF and INH, respectively, are now commercially
available (3, 8, 13).
Resistance to ﬂuoroquinolones, such as oﬂoxacin (OFX),
commonly used to treat MDR-TB is thought to be mediated by
mutations (single nucleotide polymorphisms [SNPs]) in the
target genes gyrA and, less frequently, gyrB, which encode the
respective subunits of the DNA topoisomerase gyrase (24).
Most mutations conferring resistance to quinolones are known
to accumulate in a short discrete region of the gyrA and gyrB
genes termed the quinolone resistance-determining region
(QRDR) (2).
Resistance to the aminoglycoside AMK and to CM are as-
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 sociated with SNPs in the 16S rRNA gene (rrs), especially in
the region between nucleotides 1400 and 1500 (1, 23). Resis-
tance to CM is thought to be additionally mediated by muta-
tions located anywhere in the tlyA gene, which encodes a 2-
O-methyltransferase (10, 15).
In the study described here, we aimed to determine if
molecular analyses of target genes could be used for the rapid,
speciﬁc, and sensitive detection of resistance to second-line
drugs among new cases of TB and among previously treated
patients in a high-incidence setting.
Sequence analyses of the genes associated with ﬂuoroquin-
olone resistance (gyrA and gyrB) and aminoglycoside or CM
resistance (rrs and tlyA) were carried out with a panel of MDR-
and XDR-TB strains arising from an MDR-TB treatment pro-
gram in Karakalpakstan, a region in Uzbekistan with a high
incidence of anti-TB drug resistance. Genetic data were then
correlated with the results of phenotypic resistance testing.
MATERIALS AND METHODS
Mycobacterial strains and growth conditions. All mycobacterial strains used in
this study were obtained from a program for the treatment of MDR-TB in
Karakalpakstan, a region in the western part of Uzbekistan. The setting and
treatment protocols employed have been described earlier (4). The region hosts
a population of about 1.6 million people and is a high-incidence setting for TB
(120/100,000 population), with 13% of MDR-TB cases occurring among new
cases of TB and 40% of MDR-TB cases occurring among previously treated
patients (4).
Testing for susceptibility to ﬁrst- and second-line drugs (INH, RIF, ethambu-
tol, pyrazinamide, streptomycin, AMK, OFX, CM) was carried out as described
earlier (7, 17, 21). For quality assurance, the laboratory participates in the
external quality assessment program of the supranational laboratory network.
Further details can be found in the supplemental material.
During the study period from October 2003 to February 2006, 476 strains from
266 MDR-TB patients were analyzed. Among these strains, 26 OFX-resistant
isolates were identiﬁed; 3 were obtained from patients whose isolates had OFX
resistance at the baseline (which means that the ﬁrst isolate obtained already
showed resistance) and 23 were obtained from patients whose isolates developed
OFX resistance at some point during therapy. AMK and/or CM resistance was
found in 48 strains; 34 of these strains were from patients whose isolates had
resistance at the baseline, and 14 were from patients whose isolates developed
resistance during therapy (Fig. 1). Among these 48 strains, 5 were resistant to
AMK but not to CM and 3 were resistant to CM but not to AMK.
Overall, 13 strains simultaneously showed resistance to OFX and injectable
agents and were therefore XDR. Altogether, 149 strains (26 OFX-resistant
strains and 48 injectable agent-resistant strains, of which 13 were XDR) were
analyzed. Eighty-eight strains (either OFX or injectable agent susceptible)
were randomly chosen as controls. Among this collection of strains, 49 strains
were used as OFX-susceptible control strains and 39 were used as AMK- and
CM-susceptible control strains.
DNA isolation, PCR, and sequencing. Genomic DNA was isolated as de-
scribed previously (25). Sequencing was performed by a modiﬁed, nonradioactive
mode of the dideoxynucleotide chain-terminating method of Sanger et al. (22) by
using a commercial kit (Applied Biosystems, Darmstadt, Germany) and a 3130xl
genetic analyzer. Details are described in the supplemental material.
RESULTS
Mutations were observed in the QRDRs of gyrA and gyrB in
25 of the 26 (96%) OFX-resistant strains, while none of the
OFX-susceptible strains displayed mutations (Table 1).
The majority of OFX-resistant strains carried a mutation in
a short hot-spot region of 15 bases in the gyrA gene ranging
from codon 90 to codon 94 (23/26 strains [89%]), with muta-
tions predominantly occurring at codon 94 (numbering of the
codons is according to the TubercuList annotation). The
most frequent single mutation detected was the substitution
of adenine to guanine in gyrA at codon 94, which led to an
amino acid change of aspartic acid to glycine (10/26 strains
[38.5%]). Further mutations at codon 94 resulted in amino acid
changes to alanine, asparagine, histidine, and tyrosine. All
strains with mutations at codon 90 showed a change from
cytosine to thymine, which led to an amino acid change of
alanine to valine. At codon 91, a change of serine (TCG) for
proline (CCG) was found in one strain. No double mutations
were detected.
Only two OFX-resistant strains showed SNPs in gyrB exclu-
sively; neither of these changes has been reported previously
(Table 1). One of these strains had a change from cytosine to
thymine, resulting in the replacement of Arg485 with cysteine.
The second strain carried a gyrB mutation at codon 543. This
isolate showed both the wild-type sequence (Ala [GCG]) and
the variant sequence (Thr [ACG]), suggesting that the speci-
FIG. 1. Study design. Overall, 13 strains simultaneously showed
resistance to OFX and injectable agents and were therefore XDR.
Among the strains OFX resistant at the baseline, one also showed
resistance to AMK and CM, whereas 12 strains which developed OFX
resistance during therapy showed resistance to the injectable agents as
well. Only one strain from the same patient was included and was
either the baseline isolate or the ﬁrst isolate found to be resistant at
follow-up. R, resistance; *, the isolates obtained during therapy were
from both ampliﬁcation (infection with the same strain) and reinfec-
tion cases.
TABLE 1. Mutations in the QRDRs of gyrA and gyrB
a
Codon with gyrA or gyrB mutation, amino
acid (nucleotide) change
No. (%) of strains:
Resistant
to OFX
Susceptible
to OFX
No mutation 1 (3.8) 49
gyrA 90, Ala (GCG) 3 Val (GTG) 5 (19.2)
gyrA 91, Ser (TCG) 3 Pro (CCG) 1
gyrA 94, Asp (GAC) 3 Gly (GGC) 10 (38.5)
gyrA 94, Asp (GAC) 3 Asn (AAC) 1
gyrA 94, Asp (GAC) 3 Ala (GCC) 4 (15.4)
gyrA 94, Asp (GAC) 3 His (CAC) 1
gyrA 94, Asp (GAC) 3 Tyr (TAC) 1
gyrB 485, Arg (CGT) 3 Cys (TGT) 1
gyrB 543, Ala (GCG) 3 Ala (GCG)
 Thr (ACG)
1
Total 26
b 49
a For the detection of OFX resistance, sequence analyses of gyrA and gyrB had
a sensitivity and a speciﬁcity of 96.2 and 100%, respectively.
b Twenty-three strains were follow-up strains.
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 men may have been collected during the development of re-
sistance during a period when the resistant variant has not
outcompeted the susceptible bacilli, a phenomenon known as
heteroresistance (20). Sequence analyses of gyrA and gyrB had
a sensitivity and a speciﬁcity of 96.2 and 100%, respectively, for
the detection of OFX resistance among the strains analyzed.
To determine the molecular basis of resistance to the sec-
ond-line injectable agents AMK and CM, the rrs and tlyA
regions of 48 resistant strains and 39 susceptible strains were
sequenced. Table 2 shows the mutations in the resistance-
determining region of rrs and in tlyA as well as the correspond-
ing resistance phenotypes. The most common mutation de-
tected was the change of adenine to guanine at position 1401
(34/48 strains [71.0%]) in rrs and was found only in strains
resistant to both AMK and CM. One additional strain that
was resistant only to CM displayed a C1402T mutation in rrs.
Three resistant strains showed variations in tlyA. The change of
thymine to guanine at codon 160, which leads to an amino acid
change of leucine to tryptophan, appears to confer resistance
to both AMK and CM. Two SNPs, one at codon 18 (Arg
[CGA] 3 stop [TGA]) and one at codon 118 (Leu [CTG] 3
Arg [CGG]), were found in strains resistant only to CM. The
SNPs at codons 160 and 118 have not been described previ-
ously.
Among strains resistant to CM and/or AMK, 10 did not
carry a mutation in rrs or tlyA. Interestingly, all strains resistant
to AMK alone (n  5) belonged to this group. Among the
control group of 39 susceptible strains, none carried a mutation
in either rrs or tlyA. Thus, the sensitivity and the speciﬁcity of
the DNA sequencing of rrs and tlyA for the detection of sec-
ond-line injectable drug resistance were 79.2% and 100%, re-
spectively.
The practical adaptability of this method is demonstrated in
an example in which the correlation between the mutations
detected and phenotypic resistance for isolates taken from a
single patient who developed XDR-TB during therapy is
shown (see Table S2 in the supplemental material). Prior to
treatment, the baseline strain was susceptible to OFX, CM,
and AMK but later developed resistance to all three drugs
during therapy. No mutations were detected in the baseline
isolate, while all three resistant isolates in follow-up samples
carried the same mutation in gyrA at codon 94 and at position
1401 in rrs. The fact that all isolates had identical ﬁngerprints
(data not shown) demonstrates the development of resistance
during treatment rather than reinfection in this case (5).
DISCUSSION
Resistance to second-line drugs is a major factor mediating
poor treatment outcomes in the treatment of drug-resistant
TB. It is therefore essential to rapidly identify resistance to
second-line drugs prior to and during treatment, in order to
effectively guide treatment regimens. This study clearly dem-
onstrates the potential of sequence analyses of short genomic
regions to detect the major mutations mediating XDR-TB. In
addition to known mutations, additional variations involved in
second-line drug resistance in M. tuberculosis have been deter-
mined. Interestingly, the ability to confer resistance to second-
line injectable agents appears to depend on the particular
mutation, pointing to the possibility of resistance mutation-
guided therapy.
Among the OFX-resistant strains investigated in the present
study, the majority displayed SNPs in gyrA at codons 94 and 90.
These mutations have previously been described as mediating
resistance to quinolones (2). The different substitutions ob-
served at position Asp94 in this study were also among those
noted in ﬂuoroquinolone-resistant strains of M. tuberculosis
by Takiff et al. (24). In particular, the change to glycine at
codon 94 occurs most frequently, probably because this muta-
tion provides the greatest advantage for the cell concerning
increased resistance and the least loss of ﬁtness (24).
Mutations in gyrB occur less frequently than mutations in
gyrA. However, two different mutations have been detected
in this study, at codons 485 and 543, and neither mutation has
been described previously. The strains with these two muta-
tions exclusively carry the gyrB mutation and no additional
mutation in gyrA. Previously, mutations in gyrB have been de-
scribed to occur together with a gyrA mutation, leading to
high-level resistance (11). However, single mutations in gyrB
have recently been reported (19, 26, 27). While this study
reafﬁrms the impact of mutations in gyrA on the development
of ﬂuoroquinolone resistance, the results suggest that muta-
tions in gyrB should also be considered when one is screening
for XDR strains.
Only one OFX-resistant strain analyzed had no mutation in
the QRDR of either gyrA or gyrB. This strain possibly carries a
mutation which is located outside the QRDRs, or the resis-
tance may be caused by other mechanisms, such as enhanced
drug efﬂux (16).
The most frequent mutation associated with resistance to
both AMK and CM was found in rrs at nucleotide 1401. Cross-
resistance to AMK, CM, and kanamycin has recently been
described as being mediated by mutations in rrs (nucleotides
1401, 1402, and 1484) (14). The results of the analyses per-
formed in this study support the existing data that the A1401G
mutation in rrs actually mediates resistance to both AMK
and CM.
However, our results clearly show that the resistance-con-
TABLE 2. Mutations in the resistance-determining region of rrs
and in tlyA
a
rrs nucleotide change, and
tlyA codon, amino acid
(nucleotide) change
No. (%) of strains:
Resistant to
both AMK
and CM
Resistant
only to
AMK
Resistant
only to
CM
Susceptible to
AMK and
CM
No mutation 5 5 39
rrs 1401, A 3 G 34 (70.8)
rrs 1402, C 3 T1
tlyA 18, Arg (CGA) 3
stop (TGA)
1
tlyA 118, Leu (CTG) 3
Arg (CGG)
1
tlyA 160, Leu (TTG) 3
Trp (TGG)
1
Total 40
b 5
c 3
d 39
a Mixed infections were excluded from the analyses. The sensitivity and the
speciﬁcity of the DNA sequencing of rrs and tlyA for the detection of second-line
injectable drug resistance were 79.2% and 100%, respectively.
b Thirty-one strains were resistant at the baseline.
c One strain was resistant at the baseline.
d Two strains were resistant at the baseline.
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 ferring potential of mutations in tlyA is dependent on the kind
of mutation. As tlyA mutations have been detected in sponta-
neous CM-resistant M. tuberculosis mutants (15), the protein
that is encoded has been proposed to be a drug target. In this
study, one mutation at codon 160 was found in a strain resis-
tant to AMK and CM, while mutations at codon 18 and at
codon 118 were found exclusively in strains resistant to CM
only. Thus, these mutations could be regarded as genetic mark-
ers for CM resistance, while it must be borne in mind that in
the case of the strain resistant to both AMK and CM, a second
mutation might confer resistance to AMK.
No mutation was detected in either rrs or tlyA in 10 strains,
although these isolates were resistant to both AMK and CM or
to AMK alone. Mutations outside the resistance-determining
region are probably responsible for the resistance phenotype
or, possibly, enhanced multidrug efﬂux (6). Interestingly, none
of the strains which were resistant only to AMK carried a
mutation in the regions of rrs and tlyA analyzed. These results
point to so far undeﬁned resistance mechanisms that mediate
resistance to AMK alone and represent an interesting target
for future studies.
In conclusion, sequence analyses of short regions of gyrA,
gyrB, rrs, and tlyA showed a high sensitivity and a high speci-
ﬁcity for the detection of resistance to second-line drugs
among isolates from the study population. This allows the
potential development of rapid PCR assays for the detection of
second-line TB drug resistance among isolates from both new
cases and previously treated patients.
The rapid detection of second-line TB drug resistance is of
importance in guiding appropriate treatment regimens and in
increasing infection control measures that may well limit the
spread of TB.
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